Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis

  • Sci Immunol. 2018 Aug 24;3(26):eaat2738. doi: 10.1126/sciimmunol.aat2738.
Joseph K Rathkey  1 Junjie Zhao  2 Zhonghua Liu  1 Yinghua Chen  3 Jie Yang  1  3 Hannah C Kondolf  1 Bryan L Benson  1 Steven M Chirieleison  1 Alex Y Huang  1  4 George R Dubyak  3 Tsan S Xiao  1 Xiaoxia Li  2 Derek W Abbott  5
Affiliations
  • 1. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • 2. Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • 3. Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • 4. Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • 5. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. [email protected].
Abstract

Dysregulation of inflammatory cell death is a key driver of many inflammatory diseases. Pyroptosis, a highly inflammatory form of cell death, uses intracellularly generated pores to disrupt electrolyte homeostasis and execute cell death. Gasdermin D, the pore-forming effector protein of Pyroptosis, coordinates membrane lysis and the release of highly inflammatory molecules, such as interleukin-1β, which potentiate the overactivation of the innate immune response. However, to date, there is no pharmacologic mechanism to disrupt Pyroptosis. Here, we identify necrosulfonamide as a direct chemical inhibitor of gasdermin D, the pyroptotic pore-forming protein, which binds directly to gasdermin D to inhibit Pyroptosis. Pharmacologic inhibition of pyroptotic cell death by necrosulfonamide is efficacious in sepsis models and suggests that gasdermin D inhibitors may be efficacious clinically in inflammatory diseases.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • 99.70%, IAP Inhibitor
    target: IAP
    Research Areas: Cancer